Mark Sheptoff Financial Planning LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 11.8% in the second quarter, according to its most recent filing with the SEC. The fund owned 44,698 shares of the biopharmaceutical company’s stock after selling 5,955 shares during the quarter. Pfizer comprises approximately 1.0% of Mark Sheptoff Financial Planning LLC’s holdings, making the stock its 25th largest holding. Mark Sheptoff Financial Planning LLC’s holdings in Pfizer were worth $1,501,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. ARGI Investment Services LLC raised its holdings in Pfizer by 80.5% during the 2nd quarter. ARGI Investment Services LLC now owns 52,806 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 23,554 shares during the period. Covington Investment Advisors Inc. raised its holdings in Pfizer by 4.4% during the 2nd quarter. Covington Investment Advisors Inc. now owns 72,122 shares of the biopharmaceutical company’s stock valued at $2,423,000 after buying an additional 3,025 shares during the period. Commerce Bank raised its holdings in Pfizer by 1.4% during the 2nd quarter. Commerce Bank now owns 2,570,619 shares of the biopharmaceutical company’s stock valued at $86,347,000 after buying an additional 35,502 shares during the period. Newman Dignan & Sheerar Inc. raised its holdings in Pfizer by 6.3% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 45,063 shares of the biopharmaceutical company’s stock valued at $1,514,000 after buying an additional 2,664 shares during the period. Finally, NBT Bank N A NY raised its holdings in Pfizer by 0.5% during the 2nd quarter. NBT Bank N A NY now owns 230,427 shares of the biopharmaceutical company’s stock valued at $7,740,000 after buying an additional 1,063 shares during the period. Hedge funds and other institutional investors own 69.89% of the company’s stock.

In related news, EVP Alexander R. Mackenzie sold 7,350 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the sale, the executive vice president now owns 117,432 shares of the company’s stock, valued at $4,186,450.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Alexander R. Mackenzie sold 14,700 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 60,280 shares of company stock worth $2,118,988. 0.06% of the stock is owned by corporate insiders.

A number of analysts have weighed in on the company. Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. BMO Capital Markets set a $37.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Tuesday, October 10th. Barclays set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a research note on Wednesday, October 11th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Finally, Jefferies Group set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a research note on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $38.77.

Pfizer Inc. (PFE) traded down $0.43 on Wednesday, hitting $35.63. The stock had a trading volume of 22,320,600 shares, compared to its average volume of 19,989,418. Pfizer Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The company has a market cap of $211,960.00, a P/E ratio of 14.42, a price-to-earnings-growth ratio of 2.54 and a beta of 1.01.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. During the same quarter last year, the company earned $0.61 earnings per share. The firm’s revenue for the quarter was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, December 1st. Investors of record on Friday, November 10th were given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a yield of 3.59%. The ex-dividend date was Thursday, November 9th. Pfizer’s payout ratio is currently 78.53%.

TRADEMARK VIOLATION WARNING: This news story was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/12/06/mark-sheptoff-financial-planning-llc-lowers-stake-in-pfizer-inc-pfe.html.

Pfizer Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.